<DOC>
	<DOCNO>NCT01333904</DOCNO>
	<brief_summary>The purpose study establish single multiple dose safety healthy subject subject mild chronic pulmonary obstructive disease ( COPD ) . In addition , study evaluate preliminary proof concept endpoint COPD subject biomarkers sputum mucociliary clearance .</brief_summary>
	<brief_title>Safety , Tolerability , Pharmacodynamic Effect Study PUR118</brief_title>
	<detailed_description>The propose initial trial healthy subject subject mild COPD establish tolerability PUR118 subject single short multi-day dosing period . The study also provide preliminary data regard PUR118 's potential impact biomarkers COPD . Finally , trial ass PUR118 's effect mucociliary clearance . This four part study enrol healthy volunteer single ascend dose design ( SAD ; Part I ) , follow multiple ascend dose design ( MAD ; Part II ) . Contingent demonstration safety healthy subject population , study enroll mild COPD subject short multi-dose design ( Part III ) incorporate safety pharmacodynamic endpoint . Lastly Part IV trial ass effect PUR118 mucociliary clearance mild COPD subject .</detailed_description>
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Lung Diseases , Obstructive</mesh_term>
	<mesh_term>Pulmonary Disease , Chronic Obstructive</mesh_term>
	<criteria>Main Inclusion Criteria Parts I &amp; II Healthy male non pregnant , non lactate healthy female ; Age 1865 year age ; Must willing able communicate English participate whole study ; Must provide write informed consent . Main Exclusion Criteria Parts I &amp; II Current smoker smoke within last 12 month ; Females child bear age willing use acceptable form contraception ; Presence history allergy require treatment ; Serious adverse reaction hypersensitivity drug ; Main Parts III IV Males non pregnant , non lactating female ; Age 4570 year ; Current ( Part III ) exsmokers least 15 packyear smoke history . For Part IV , subject must nonsmoker least 3 month ; Medically stable , evidence uncontrolled coexist condition screen ; Must take inhaled oral corticosteroid ; FEV1/FVC ratio &lt; 70 % FEV1 60 80 % ( &gt; /= 60 % Part IV ) predict follow administration bronchodilator ; Patients must medical history COPD confirm General Practitioner ( GP ) treat hospital physician must chest xray ( CXR ) normal consistent mild COPD exclude clinically significant respiratory abnormality ; Must willing able communicate English participate whole study ; Must provide write informed consent . Main Parts III IV Must agree use adequate method contraception ; Upper respiratory tract infection within 30 day first study day , low respiratory tract infection within last 60 day ; Patients take medication may affect respiratory tract within 14 day first study day usual COPD medication ; No active exacerbation require antibiotic steroid within 60 day dose .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>September 2012</verification_date>
</DOC>